[A19-61] Pembrolizumab (non-squamous NSCLC, combination chemotherapy) - Addendum to commission A19-30
Last updated 19.09.2019
Commission awarded on 05.08.2019 by the Federal Joint Committee (G-BA).
First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations
PD-L1 expression < 50%: proof of major added benefit for women, indication of minor added benefit for men. PD-L1 expression ≥ 50%: hint of major added benefit for women, hint or lesser benefit for men
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.